National Bank Of Canada Fate Therapeutics Inc Transaction History

National Bank Of Canada

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 02, 2024	BUY	$3.26 - $7.08 $32 - $70	10 Added 2.5%	410 $1,000
Q1 2024 May 13, 2024	SELL	$3.54 - $8.35 $23,364 - $55,110	-6,600 Reduced 94.29%	400 $2,000
Q4 2023 Feb 06, 2024	SELL	$1.65 - $3.94 $8,250 - $19,700	-5,000 Reduced 41.67%	7,000 $26,000
Q3 2023 Oct 10, 2023	BUY	$2.02 - $5.04 $24,240 - $60,480	12,000 New	12,000 $25,000
Q3 2022 Oct 13, 2022	SELL	$21.04 - $36.06 $10,520 - $18,030	-500 Reduced 50.0%	500 $11,000
Q2 2022 Jul 28, 2022	BUY	$17.78 - $42.39 $17,780 - $42,390	1,000 New	1,000 $25,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $143M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of National Bank Of Canada , based on Form 13F filings with the SEC.

Stay updated on National Bank Of Canada with notifications on news.